A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer

Annals of Oncology

Volumn 13, Issue 4, 2002, Pages 539-545

  Rudin, C M ^a   Otterson, G A ^b   Mauer, A M ^a   Villalona Calero, M A ^b   Tomek, R ^a   Prange, B ^a   George, C M ^a   Szeto, L ^a   Vokes, E E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Chemoresistance; Phosphorothioate; Translational inhibition

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; FAMOTIDINE; MESSENGER RNA; OBLIMERSEN; ONDANSETRON; PACLITAXEL; PROTEIN BCL 2;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; GENE EXPRESSION; HEMATOLOGIC DISEASE; HUMAN; LUNG SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BCL-2; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 0036236808     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf124     Document Type: Article

References (43)

1. Cancer statistics, 2000
2. Current management of small cell lung cancer
3. Overview of chemotherapy for small cell lung cancer
4. New chemotherapy agents for small-cell lung cancer
5. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patient with refractory and sensitive disease
6. Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC)
7. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
8. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
9. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: A phase II study of the North Central Cancer Treatment Group
10. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
11. Expression of bcl-2 in small cell lung carcinoma cells
12. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas
13. Immunohistochemical detection of Bcl-2 protein in small cell carcinomas
14. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells
15. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
16. Bcl-2: Prevention of apoptosis as a mechanism of drug resistance
17. Bcl-2 gene transfer increases relative resistance of S49:1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs
18. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis
19. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma
20. Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways
21. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
22. L protein levels
23. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression
24. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
25. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides
26. Antisense oligonucleotides as therapeutic agents
27. Preclinical and clinical pharmacology of antisense oligonucleotides
28. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL
29. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
30. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
31. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
32. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
33. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model
34. Tumor regression of human breast carcinomas by combination therapy of anti-Bcl-2 antisense oligonucleotide and chemotherapeutic drugs
35. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M
36. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
37. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
38. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
39. A phase I, pharmacokinetic, and biologic correlative study of G3193 and irinotecan (CPT-11) in patients with metastatic colorectal cancer
40. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
41. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities
42. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
43. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death